A dose-finding clinical trial of mushroom powder in postmenopausal breast cancer survivors for secondary breast cancer prevention.

Palomares, Melanie R.; Rodríguez, J.; Phung, S.; Stanczyk, F.Z.; Lacey, Susan R.; Synold, Timothy W.; Denison, Stacy R.; Frankel, Paul; Chen, S.

doi:10.1200/jco.2011.29.15_suppl.1582

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to ascertain the optimal dose of A . bisporus , or white button mushroom (WBM), to achieve in humans the effects of suppressing aromatase activity and inhibiting breast cancer cell proliferation already established in vitro and in preclinical tests, Palomares et al [ 114 ] carried out the following dose-finding study: a 12-week course of treatment with 5, 8, 10, or 13 g daily of the fungal extract in postmenopausal women previously diagnosed with breast cancer but no longer undergoing treatment and who are recurrence free. Aromatase inhibition by aromatase activity (AA) tests and a decrease in free estradiol (FE2) and cytokine levels were the counted parameters.…”

Section: Pharmacological Activities Of Mushrooms: Medical Evidencementioning

confidence: 99%

Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials

Venturella

Ferraro

Cirlincione

et al. 2021

IJMS

198

108

View full text Add to dashboard Cite

Medicinal mushrooms have important health benefits and exhibit a broad spectrum of pharmacological activities, including antiallergic, antibacterial, antifungal, anti-inflammatory, antioxidative, antiviral, cytotoxic, immunomodulating, antidepressive, antihyperlipidemic, antidiabetic, digestive, hepatoprotective, neuroprotective, nephroprotective, osteoprotective, and hypotensive activities. The growing interest in mycotherapy requires a strong commitment from the scientific community to expand clinical trials and to propose supplements of safe origin and genetic purity. Bioactive compounds of selected medicinal mushrooms and their effects and mechanisms in in vitro and in vivo clinical studies are reported in this review. Besides, we analyzed the therapeutic use and pharmacological activities of mushrooms.

show abstract

Section: Pharmacological Activities Of Mushrooms: Medical Evidencementioning

confidence: 99%

Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials

Venturella

Ferraro

Cirlincione

et al. 2021

IJMS

198

108

View full text Add to dashboard Cite

show abstract

“…Conjugated linoleic acid was identified as an active component with anti-aromatase activity [10] . Based on our preclinical data, a clinical trial of WBM is currently underway in postmenopausal, ER-positive breast cancer survivors to determine whether clinically detectable estrogen suppression can be achieved [14] . Although mukitake mushroom was reported to improve NAFLD, due to the observed anti-aromatase effect of WBM, there were clinical concerns that the resulting decrease in estrogen in women could exacerbate NAFLD in postmenopausal women.…”

Section: Introductionmentioning

confidence: 99%

Protective Effects of White Button Mushroom (Agaricus bisporus) against Hepatic Steatosis in Ovariectomized Mice as a Model of Postmenopausal Women

et al. 2011

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) includes various hepatic pathologies ranging from hepatic steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Estrogen provides a protective effect on the development of NAFLD in women. Therefore, postmenopausal women have a higher risk of developing NAFLD. Hepatic steatosis is an early stage of fatty liver disease. Steatosis can develop to the aggressive stages (nonalcoholic steatohepatitis, fibrosis and cirrhosis). Currently, there is no specific drug to prevent/treat these liver diseases. In this study, we found that white button mushroom (WBM), Agaricus Bisporus, has protective effects against liver steatosis in ovariectomized (OVX) mice (a model of postmenopausal women). OVX mice were fed a high fat diet supplemented with WBM powder. We found that dietary WBM intake significantly lowered liver weight and hepatic injury markers in OVX mice. Pathological examination of liver tissue showed less fat accumulation in the livers of mice on WBM diet; moreover, these animals had improved glucose clearance ability. Microarray analysis revealed that genes related to the fatty acid biosynthesis pathway, particularly the genes for fatty acid synthetase (Fas) and fatty acid elongase 6 (Elovl6), were down-regulated in the liver of mushroom-fed mice. In vitro mechanistic studies using the HepG2 cell line showed that down-regulation of the expression of FAS and ELOVL6 by WBM extract was through inhibition of Liver X receptor (LXR) signaling and its downstream transcriptional factor SREBP1c. These results suggest that WBM is protective against hepatic steatosis and NAFLD in OVX mice as a model for postmenopausal women.

show abstract

“…Our search yielded a total of 272 studies from the electronic databases. After sorting out repetitive hits, irrelevant and several single arm studies with various outcomes, e.g., dose escalation studies (Kodama et al, 2002;Gao et al, 2003b;Yoshimura et al, 2010;Palomares et al, 2011;Torkelson et al, 2012;Ohno et al, 2013;Suzuki et al, 2013;Twardowski et al, 2015) as well as many publications on in vitro and animal models, nine studies met our inclusion and exclusion criteria for a narrative review on medicinal mushrooms in human cancer therapy (eight RCTs, one CCT) ( Table 1). A large variety of cancer entities, studied sample sizes, outcomes, treatment durations and observation times were seen ( Table 1).…”

Section: Resultsmentioning

confidence: 99%

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

et al. 2020

View full text Add to dashboard Cite

Medicinal mushrooms are widely used in East Asia for the treatment of various diseases, especially in complementary cancer care. While there is a growing interest in medicinal mushrooms in Western countries and an increasing number of pre-clinical studies indicate distinct anti-cancer and regenerative properties, little is known about their potential relevance for clinical practice. This review aims to provide an overview of the clinical evidence, significance and potential role of medicinal mushrooms in complementary cancer care. Scientific databases for (randomized) controlled clinical trials evaluating whole spectrum formulations of medicinal mushrooms (mushroom powder and mushroom extracts) in cancer patients during and/or after conventional oncological treatment were searched. Eight studies met our inclusion criteria (eight randomized controlled trials, one controlled clinical trial). The medicinal mushrooms investigated were Agaricus sylvaticus (two trials), Agaricus blazei murill (two trials), Antrodia cinnamomea (one trial), Coriolus versicolor (one trial) and Ganoderma lucidum (three trials); all were compared to placebo and administered orally. A variety of cancer entities, outcomes and treatment durations were observed. Study results suggested beneficial effects of medicinal mushrooms, particularly quality of life and reduction of adverse effects of conventional therapies. Also, positive effects on antitumor activity and immunomodulation were reported, e.g., an increased activity of natural killer cells. In addition, results might suggest a longer survival of cancer patients receiving mushroom preparations, although in most studies this was not significant when compared to placebo. Adverse events of treatment with medicinal mushrooms were poorly reported; gastrointestinal reactions and a decrease in platelet cell count occurred in some cases. The methodological quality of most studies was generally unsatisfying and most results were insufficiently reported in several respects. Medicinal mushrooms may have a therapeutic potential for cancer patients during and after conventional oncological care with regards to quality of life, reduction of adverse effects of conventional care and possibly other surrogate parameters like immune function. There is an urgent need to investigate the safety and possible interactions of medicinal mushrooms. High-quality clinical research is warranted in order to clarify the potential of medicinal mushrooms in cancer therapy.

show abstract

A dose-finding clinical trial of mushroom powder in postmenopausal breast cancer survivors for secondary breast cancer prevention.

Cited by 7 publications

References 0 publications

Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials

Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials

Protective Effects of White Button Mushroom (Agaricus bisporus) against Hepatic Steatosis in Ovariectomized Mice as a Model of Postmenopausal Women

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

Contact Info

Product

Resources

About